Valneva SE (LON:0OB3)
3.498
-0.009 (-0.26%)
Dec 19, 2025, 5:13 PM BST
Valneva SE Employees
Valneva SE had 713 employees as of December 31, 2024. The number of employees increased by 37 or 5.47% compared to the previous year.
Employees
713
Change (1Y)
37
Growth (1Y)
5.47%
Revenue / Employee
220.25K GBP
Profits / Employee
-125.07K GBP
Market Cap
536.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 713 | 37 | 5.47% |
| Dec 31, 2023 | 676 | -43 | -5.98% |
| Dec 31, 2022 | 719 | -43 | -5.64% |
| Dec 31, 2021 | 762 | 262 | 52.40% |
| Dec 31, 2020 | 500 | -21 | -4.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Convatec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
| HUTCHMED (China) | 1,811 |
Valneva SE News
- 10 days ago - Valneva (VALN) Reveals Positive Phase 2 Data for Chikungunya Vaccine - GuruFocus
- 10 days ago - Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 15 days ago - VALNEVA Declaration of shares and voting rights: November 30, 2025 - GlobeNewsWire
- 24 days ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 24 days ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 24 days ago - Valneva to Further Consolidate its Operations in France - GlobeNewsWire
- 24 days ago - Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study - WSJ
- 24 days ago - Valneva's Lyme Vaccine VLA15 Shows Strong Phase 2 Booster Results With Favorable Safety - Nasdaq